Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

Background and Aims: In patients with <i>Rat sarcoma proto-oncogene</i> (<i>RAS</i>) wild-type metastatic colorectal cancer (mCRC), anti-epidermal growth factor receptor (EGFR) antibodies have been established in first- and further therapy lines. Due to limited treatment opti...

Full description

Bibliographic Details
Main Authors:	Martin S. Schulz, Sebastian Wolf, Vera Struck, Niklas Thomas, Gabriele Husman, Stefan Zeuzem, Christine Koch, Jörg Trojan, Andreas Anton Schnitzbauer, Wolf Otto Bechstein, Oliver Waidmann
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Cancers
Subjects:	chemorefractory metastatic colorectal cancer anti-EGFR therapy re-exposure rechallenge reintroduction
Online Access:	https://www.mdpi.com/2072-6694/14/7/1641

Similar Items

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
by: Alessio Amatu, et al.
Published: (2022-02-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01)

An Improvement of Exertional Dyspnea by the Reintroduction of Anti-EGFR Antibody in Patients with Metastatic Rectal Cancer Who Developed Cancerous Lymphangiopathy: A Case Report
by: Masatsune Shibutani, et al.
Published: (2024-03-01)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
by: Meiqin Yuan, et al.
Published: (2022-03-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
by: Davide Ciardiello, et al.
Published: (2023-04-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
by: Stefano Mariani, et al.
Published: (2022-04-01)

Classic Hodgkin lymphoma-nodular sclerosis – case report
by: Mihaela Lebedenco, et al.
Published: (2023-06-01)

Classic Hodgkin Lymphoma – mixed cellularity – case report and review of literature
by: Mihaela Oprea-Lebedenco, et al.
Published: (2023-03-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
by: Christine Parseghian, et al.
Published: (2023-09-01)

Melanoma: BRAFi Rechallenge
by: Christoforos S. Kosmidis, et al.
Published: (2023-05-01)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by: Adrian Perdyan, et al.
Published: (2023-07-01)

Ofloxacin-ornidazole fixed-dose combination medication-induced pancreatitis with positive rechallenge
by: Nikhil Bush, et al.
Published: (2020-01-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by: Federica Frascaro, et al.
Published: (2023-12-01)

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
by: Maria Effrosyni Livanou, et al.
Published: (2024-03-01)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
by: Yuto Terashima, et al.
Published: (2022-12-01)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
by: Annabel H. S. Alig, et al.
Published: (2022-01-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
by: Florian Huemer, et al.
Published: (2018-01-01)

ROUNDTABLE SESSION 4A: MANAGEMENT: REINTRODUCTIONS AND RESTOCKING.
by: SCHULZ R., et al.
Published: (2002-07-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Factors affecting attitudes toward reintroduction of wolves in Japan
by: Ryo Sakurai, et al.
Published: (2020-06-01)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
by: Manon Réda, et al.
Published: (2023-04-01)